New drug tested to slow ALS progression
NCT ID NCT00415519
Summary
This study tested whether a drug called MCI-186 could help control the progression of ALS (Lou Gehrig's disease). It involved 25 people with moderate ALS who received either the drug or a placebo through daily IV infusions for 24 weeks. Researchers measured changes in physical function, breathing ability, and safety to see if the treatment was effective and well-tolerated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.